Introduction {#Sec1}
============

The incidence rate of thyroid cancer rose rapidly in recent decades^[@CR1]^. However, the incidence rate of thyroid cancer also appears to have begun to stabilize in recent years, since changes in clinical practice guidelines were initiated in 2009^[@CR2]^. Papillary thyroid cancer (PTC) accounts for 80--90% of all thyroid malignancies, making it the most common type of thyroid malignancy^[@CR3]--[@CR5]^.

According to World Health Organization guidelines, papillary thyroid microcarcinoma (PTMC) is defined as thyroid carcinoma measuring less than or equal to 1 cm in its greatest dimension^[@CR6]^. In recent reports, roughly 18.4% to 50% of the increase in PTC has been attributed to the identification of intrathyroidal papillary thyroid microcarcinomas^[@CR7]--[@CR11]^.

According to previous studies, it is still controversial whether male gender a poor prognostic factor in cases of PTC^[@CR12],\ [@CR13]^. A recent meta-analysis demonstrated that male gender was a strong prognostic factor, and increased the risk of recurrence^[@CR14]^. Because of the contradictory results in the prior literature, a large-scale population-based cohort should be investigated to clarify the associations between gender and the prognoses of PTC and PTMC.

The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) is the largest publicly available and authoritative source of data on cancer incidence and survival. In the present study, we used this reliable and large-scale research dataset to reevaluate the prognostic significance of male gender for PTC and PTMC. Our analysis was based on the records of 43712 patients with PTCs diagnosed during 2010--2013.

Results {#Sec2}
=======

Demographic and clinical features {#Sec3}
---------------------------------

Baseline clinicopathologic characteristics are summarized and compared between men and women with PTC in Table [1](#Tab1){ref-type="table"}. The mean ± standard deviation (SD) durations of survival during the study period was 21.47 ± 14.04 months for the entire cohort of patients with PTC. Mean age was higher (53.03 ± 15.30 vs 48.68 ± 15.14 years, *p* \< 0.001) and tumor size was larger (22.48 ± 21.79 vs 16.93 ± 17.75 mm, *p* \< 0.001) in men than in women. In patients with PTC, gender was associated with race, T stage, N stage, distant metastasis, extrathyroidal extension, multifocality, radiation, and surgical method (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of Patients with Papillary Thyroid Cancer from the Surveillance, Epidemiology, and End Results Database (2010--2013).CharacteristicVariableFemale (n = 33614)Male (n = 10098)*P*AgeMean ± SD48.68 ± 15.1453.03 ± 15.30\<0.001\<45 year13597(40.5%)2962(29.3%)\<0.001 ≥ 45 year20017(59.5%)7136(70.7%)Racewhite26843(81.1%)8484(85.1%)\<0.001black2381(7.2%)502(5.0%)other3875(11.7%)989(9.9%)Tumor sizeMean ± SD16.93 ± 17.7522.48 ± 21.79\<0.001 ≤ 1.0 cm14425(42.9%)3347(33.1%)\<0.001 \> 1.0 cm19189(57.1%)6751(66.9%)T stageT121435(64.0%)5203(51.7%)\<0.001T25293(15.8%)1794(17.8%)T35956(17.7%)2595(25.8%)T4826(2.5%)473(4.7%)N stageN026685(80.7%)7047(70.9%)\<0.001N16391(19.3%)2889(29.1%)Distant metastasisNo33347(99.2%)9861(97.7%)\<0.001Yes267(0.8%)236(2.3%)Extrathyroidal extensionNo26225(84.9%)7263(79.1%)\<0.001Yes4664(15.1%)1915(20.9%)Multifocal tumorNo19884(59.8%)5525(55.5%)\<0.001Yes13355(40.2%)4436(44.5%)SurgeryNo^a^427(1.3%)201(2.0%)\<0.001Yes^b^33107(98.7%)9827(98.0%)RadiationNone or refused17793(54.3%)4689(47.8%)\<0.001performed14958(45.7%)5111(52.2%)All cause deathNo33128(98.6%)9706(96.1%)\<0.001Yes486(1.4%)392(3.9%)Cancer-specific deathNo33497(99.7%)9991(98.9%)\<0.001Yes117(0.3%)107(1.1%)^a^Recommended but not Performed OR Not recommended; ^b^Performed.

Baseline clinicopathologic characteristics are summarized and compared between men and women with PTC \> 1 cm in Table [2](#Tab2){ref-type="table"}. The mean ± SD duration of survival for patients with PTC \> 1 cm was 21.52 ± 14.00 months. Mean age was higher (52.26 ± 15.98 vs 47.31 ± 15.83 years, *p* \< 0.001) and tumor size was larger (25.53 ± 19.32 vs 30.90 ± 22.18 mm, *p* \< 0.001) in men than in women. PTC \> 1 cm in male patients was more frequently associated with race, T stage, N stage, distant metastasis, extrathyroidal extension, multifocality, radiation, and surgical method (Table [2](#Tab2){ref-type="table"}).Table 2Characteristics of Patients with Papillary Thyroid Cancer ≥ 1 cm from the Surveillance, Epidemiology, and End Results Database (2010--2013).CharacteristicVariableFemale (n = 19189)Male (n = 6751)*P*AgeMean ± SD47.31 ± 15.8352.26 ± 15.98\<0.001\<45 year8653(45.1%)2178(32.3%)\<0.001 ≥45 year10536(54.9%)4573(67.7%)Racewhite15098(79.9%)5648(84.7%)\<0.001black1347(7.1%)327(4.9%)other2452(13.0%)694(10.4%)Tumor sizeMean ± SD25.53 ± 19.3230.90 ± 22.18\<0.001T stageT17891(41.3%)2105(31.3%)\<0.001T25293(27.7%)1794(26.7%)T35155(27.0%)2369(35.3%)T4759(4.0%)452(6.7%)N stageN013727(73.2%)4300(65.1%)\<0.001N15031(26.8%)2309(34.9%)Distant metastasisNo18945(98.7%)6539(96.9%)\<0.001Yes244(1.3%)211(3.1%)Extrathyroidal extensionNo13400(77.6%)4323(71.9%)\<0.001Yes3877(22.4%)1690(28.1%)Multifocal tumorNo10560(55.9%)3503(52.7%)\<0.001Yes8355(44.1%)3139(47.3%)SurgeryNo^a^335(1.8%)173(2.6%)\<0.001Yes^b^18799(98.2%)6548(97.4%)RadiationNone or refused7045(37.8%)2309(35.3%)\<0.001performed11570(62.2%)4228(64.7%)All cause deathNo18851(98.2%)6479(96.0%)\<0.001Yes338(1.8%)272(4.0%)Cancer-specific deathNo19080(99.4%)6651(98.5%)\<0.001Yes109(0.6%)100(1.5%)^a^Recommended but not Performed OR Not recommended; ^b^Performed.

Next, we focused on the baseline clinicopathologic characteristics of patients with PTMC, which are summarized in Table [3](#Tab3){ref-type="table"}. The mean ± SD survival months for PTMC patients was 21.38 ± 14.09 months. Mean age was higher (50.50 ± 13.96 vs 54.61 ± 13.71 years, *p* \< 0.001) and tumor size was larger (5.49 ± 2.94 vs 5.49 ± 2.98 mm, *p* = 0.0909) in men than in women. PTMC in male patients was more frequently associated with race, T stage, N stage, distant metastasis, extrathyroidal extension, multifocality, and radiation (all p \< 0.05), but not with surgical method (p = 0.189) (Table [3](#Tab3){ref-type="table"}).Table 3Characteristics of Patients with Papillary Thyroid Microcarcinoma from the Surveillance, Epidemiology, and End Results Database (2010--2013).CharacteristicVariableFemale (n = 14425)Male (n = 3347)*P*AgeMean ± SD50.50 ± 13.9654.61 ± 13.71\<0.001\<45 year4944(34.3%)784(23.4%)\<0.001 ≥ 45 year9481(65.7%)2563(76.6%)Racewhite11745(82.7%)2836(85.8%)\<0.001black1034(7.3%)175(5.3%)other1423(10.0%)295(8.9%)Tumor sizeMean ± SD5.49 ± 2.945.49 ± 2.980.909T stageT113544(94.0%)3098(92.6%)0.013T3801(5.6%)226(6.8%)T467(0.4%)21(0.6%)N stageN012958(90.5%)2747(82.6%)\<0.001N11360(9.5%)580(17.4%)Distant metastasisNo14402(99.8%)3322(99.3%)\<0.001Yes23(0.2%)25(0.7%)Extrathyroidal extensionNo12825(94.2%)2940(92.9%)0.005Yes787(5.8%)225(7.1%)Multifocal tumorNo9324(65.1%)2022(60.9%)\<0.001Yes5000(34.9%)1297(39.1%)SurgeryNo^a^92(0.6%)28(0.8%)0.189Yes^b^14308(99.4%)3279(99.2%)RadiationNone or refused10748(76.0%)2380(72.9%)\<0.001performed3388(24.0%)883(27.1%)All cause deathNo14277(%)3227(%)\<0.001Yes148(%)120(%)Cancer-specific deathNo14417(99.9%)3340(99.8%)0.006Yes8(0.1%)7(0.2%)^a^Recommended but not Performed OR Not recommended; ^b^Performed.

Survival analysis of patients with PTC {#Sec4}
--------------------------------------

In a Kaplan-Meier analysis of the entire cohort of PTC patients, all-cause survival declined sharply for men, but declined more modestly for women (Log-rank test, p \< 0.001) (Fig. [1A](#Fig1){ref-type="fig"}). Similar results were observed for cause-specific survival (Log-rank test, p = 0.005) (Fig. [1B](#Fig1){ref-type="fig"}). Among patients with PTC \> 1 cm, all-cause and cause-specific survival curves were poorer for men than women (Log-rank test, both p \< 0.001) (Fig. [2A,B](#Fig2){ref-type="fig"}). Among patients with PTMC, all-cause and cause-specific survival curves were also poorer for men than women (Log-rank test; all-cause death, p \< 0.001; cancer-specific death, p = 0.005) (Fig. [3A,B](#Fig3){ref-type="fig"}).Figure 1All-cause survival (**A**) and cancer-specific survival (**B**) for men and women with papillary thyroid carcinoma. Figure 2All-cause survival (**A**) and cancer-specific survival (**B**) for men and women with papillary thyroid carcinomas \>1 cm. Figure 3All-cause survival (**A**) and cancer-specific survival (**B**) for men and women with papillary thyroid microcarcinoma.

In the entire cohort of patients with PTC, the rate of all-cause death per 1000 person-years was 7.16 (95% confidence interval \[CI\], 6.52-7.87) for men and 18.28 (95% CI, 16.40-20.37) for women (Table [4](#Tab4){ref-type="table"}). Comparing male vs. female patients, the hazard ratio (HR) for all-cause mortality was 2.53 (95% CI, 2.20-2.90). After adjustment for patient age at diagnosis, race, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis, distant metastasis, radiation, and surgical treatment, these HRs for all-cause and cause-specific mortality became 1.63 (95% CI, 1.39-1.91) and 1.67 (95% CI, 1.42-1.97), respectively. Therefore, male gender had a robust effect on all-cause death in the overall cohort of PTC patients; this effect remained even after additional adjustment for conventional clinicopathological risk factors and treatment methods (Table [4](#Tab4){ref-type="table"}). We subsequently investigated all of the abovementioned associations in subgroup analyses of patients with PTC \> 1 cm and PTMC. Similar results were observed (Table [4](#Tab4){ref-type="table"}).Table 4Hazard Ratios of sex for the all cause deaths of PTC.VersionsSexAll Cause Deaths, No.%All Cause Deaths per 1,000 Person-Years95% CIUnadjustedAdjustment 1\*Adjustment 2^†^Hazard Ratios95% CIHazard Ratios95% CIHazard Ratios95% CIAll PTCFemale4861.457.166.52--7.871 \[Reference\]1 \[Reference\]1 \[Reference\]Male3923.8918.2816.40--20.372.532.20--2.90\<0.0011.631.39--1.91\<0.0011.671.42--1.97\<0.001PTC \> 1 cmFemale3381.769.138.17--10.201 \[Reference\]1 \[Reference\]1 \[Reference\]Male2724.0320.5618.16--23.282.271.93--2.66\<0.0011.461.21--1.77\<0.0011.521.25--1.84\<0.001PTMCFemale1481.034.543.78--5.441 \[Reference\]1 \[Reference\]1 \[Reference\]Male1203.5913.5010.81--16.852.842.16--3.73\<0.0012.071.54--2.78\<0.0012.061.52--2.77\<0.001PTC: Papillary thyroid cancer; PTMC: Papillary Thyroid Microcarcinoma.\*Adjustment 1 was made for patient age at diagnosis, race, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis and distant metastasis.^†^Adjustment 2 was made for patient age at diagnosis, race, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis, distant metastasis, radiation and surgery treatment.

Furthermore, we analyzed cancer-specific deaths. In the entire cohort of patients with PTC, the rate of cancer-specific deaths per 1000 person-years was 1.76 (95% CI, 1.46-2.13) for men and 5.42 (95% CI, 4.44-6.62) for women (Table [5](#Tab5){ref-type="table"}). Comparing male vs. female patients, the HR for cancer-specific deaths was 3.09 (95% CI, 2.38-4.02). After adjustment for conventional clinicopathological risk factors and treatment methods, the HRs for cancer-specific deaths were 1.50 (95% CI, 1.10-2.06) and 1.53 (95% CI, 1.11-2.10), respectively. Similar results were observed for patients with PTC \> 1 cm. However, among patients with PTMC, the HR for cancer-specific deaths was 3.89 (95% CI, 1.41-10.71) without adjustment and 1.23 (95% CI, 0.36-4.16; p = 0.743) after adjustment for patient age at diagnosis, race, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis, and distant metastasis. Moreover, after the HR became 0.77 (95% CI, 0.19-3.16; p = 0.769) after adjustment for patient age at diagnosis, race, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis, distant metastasis, radiation, and surgical treatment (Table [5](#Tab5){ref-type="table"}).Table 5Hazard Ratios of sex for the cancer specific deaths of PTC.VersionsSexCancer Specific Deaths, No.%Cancer Specific Deaths per 1,000 Person--Years95% CIUnadjustedAdjustment 1\*Adjustment 2^†^Hazard Ratios95% CI*p*Hazard Ratios95% CI*p*Hazard Ratios95% CI*p*All PTCFemale1170.351.761.46--2. 131 \[Reference\]1 \[Reference\]1 \[Reference\]Male1071.065.424.44--6.623.092.38--4.02\<0.0011.501.10--2.060.0111.531.11--2.100.010PTC \> 1 cmFemale1090.572.912.39--3.541 \[Reference\]1 \[Reference\]1 \[Reference\]Male1001.487.436.04--9.142.622.00--3.45\<0.0011.461.05--2.020.0241.521.09--2.110.014PTMCFemale80.060.230.10--0.521 \[Reference\]1 \[Reference\]1 \[Reference\]Male70.211.210.58--2.543.891.41--10.710.0091.230.36--4.160.7430.770.19--3.160.769PTC: Papillary thyroid cancer; PTMC: Papillary Thyroid Microcarcinoma.\*Adjustment 1 was made for patient age at diagnosis, race, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis and distant metastasis.^†^Adjustment 2 was made for patient age at diagnosis, race, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis, distant metastasis, radiation and surgery treatment.

Discussion {#Sec5}
==========

Several studies have reported conflicting results regarding the effects of male gender on the prognosis of PTC. Kruijff and colleagues demonstrated the risk of structural recurrence in men was 2.44 times that in women, with a median follow-up period of 31 months^[@CR15]^. A meta-analysis also showed that male gender was an independent poor prognostic factor, and that the risk of recurrence in men was 1.53 times that in women^[@CR14]^. However, only 4 of the 13 articles included in this meta-analysis reported that male gender was a poor prognostic factor for PTC.

Oyer *et al*. concluded that there was no difference in disease-specific survival between male and female patients with the same disease stage, according to an analysis of the SEER database from 1988--2003^[@CR16]^. Nilubol and Grogan *et al*. also reported that male gender was not an independent prognostic factor of cancer specific survival in PTC patients^[@CR12],\ [@CR17]^. Similar result was also reported by Matsuzu *et al*.'s study which recorded 1088 PTC patients with a median follow-up period of 17.6 years^[@CR18]^.

These inconsistent results introduce a dilemma into the treatment of PTC. More aggressive treatment options (such as total thyroidectomy, or lymph node dissection followed by radioactive iodine ablation) should be considered for men if male gender is a negative independent prognostic factor in PTC. The purpose of this study was to investigate whether male gender was a poor prognostic factor in PTC. Throughout our analyses of the SEER database, male gender was associated with elevated risks of all-cause death and cancer-specific death, both for PTC as a whole and for PTCs \> 1 cm. Therefore, based on our results, relatively more aggressive treatment should be considered for these subgroups of patients.

Among patients with PTMC, male gender was associated with significantly elevated risks of all-cause death. However, we found that this association did not remain statistically significant after adjusting for patient age at diagnosis, race, multifocality, and other risk-associated clinicopathological characteristics and treatment methods. This may be attributable to the extremely good prognosis of PTMC, which as 15-year disease-specific survival rates as high as 99% and overall survival of 97.5%^[@CR19],\ [@CR20]^.

Recent studies have reported that estrogen can regulate thyroid cell proliferation by binding to both ERα, and ERβ. These studies attempted to investigate the associations between estrogen receptor (ER) expression and tumor aggressiveness and prognosis in PTC, but obtained inconsistent conclusions^[@CR21]--[@CR23]^. Yi *et al*. investigated the clinical implications of ER coding genes in PTC and found that ESR1 expression and the ESR ratio were associated with aggressive clinicopathological factors and poor overall survival in women^[@CR21]^. Huang *et al*. further observed that ERα stimulates PTC growth and progression, whereas ERb1 inhibits PTC growth and progression^[@CR23]^. Since ER expression levels differ between men and women, we speculate that ER level may be one of the underlying reasons for the gender differences in PTC tumor aggressiveness and prognosis. However, further research (including both genomic and epidemiologic investigations) should be performed to reveal the source of the gender disparity.

Some inherent limitations must be taken into consideration in the interpretation of our results. The major limitations of this study are that data regarding recurrence are not captured in SEER, and that designation of cancer-specific death is susceptible to overestimation bias, particularly for diseases such as PTMC. Furthermore, vascular invasion, family history, and other histologic findings were not evaluated or included in our study. In addition, the molecular markers such as *BRAF* point mutation and *TERT* promotor point mutation, were not obtained in our study or adjusted for in our analyses. Furthermore, given the generally favorable prognosis of PTC, the relatively short study period and follow-up (2010--2013) is a limitation to our analysis.

Conclusion {#Sec6}
==========

Our study demonstrated that male gender is an independent poor prognostic factor for all PTCs and for PTCs \> 1 cm. However, gender could actually have substantial prognostic relevance for PTMC, but that you do not have enough data or a long enough follow-up period to determine this reliably. These results may be instructive for clinicians. In general, more aggressive treatments should be provided to men with all PTCs and PTCs \> 1 cm.

Methods and Materials {#Sec7}
=====================

Database {#Sec8}
--------

We investigated PTC and PTMC in a large cohort of patients from SEER. The SEER project is a United States population-based cancer registry that began in 1973 and is supported by the National Cancer Institute and the Centers for Disease Control and Prevention. It covers approximately 30% of the population of the United States and contains data across multiple geographic regions on incidence, prevalence, mortality, population-based variables, primary characteristics of the tumor, and other attributes.

Data collection and analysis {#Sec9}
----------------------------

We examined SEER data for 2010--2013 and selected patients with a diagnosis of PTC, as defined by a combination of ICD-O site code of C73.9 (i.e., thyroid) and papillary histology. The following diagnostic codes were included in the study: "papillary carcinoma," "papillary adenocarcinoma," "oxyphilic adenocarcinoma", "papillary adenocarcinoma," and "papillary cyst-adenocarcinoma." Demographic information, age, sex, tumor size, extrathyroidal extension, multifocality, nodal, metastasis, surgical treatment and radiation treatment were compiled from the SEER dataset, and a survival analysis was performed to evaluate the associations between gender and prognosis.

Statistical analysis {#Sec10}
--------------------

Patients were followed up until December 2013. The outcomes measures were thyroid carcinoma-specific mortality and all-cause mortality. Patient survival curves were investigated using Kaplan-Meier analyses, log-rank tests, and Cox proportional hazards regression analyses. HRs were used to show the magnitude of the effect of stages on cancer-specific mortality. Ninety-five percent CIs were used to indicate the significance of the risks. All P values were 2-sided and P less than .05 was regarded as indicating statistical significance. Analyses were performed using SPSS version 19.0 (IBM Corp, Armonk, NY, USA), Stata/SE version 12 (Stata Corp, College Station, TX, USA), and GraphPad Prism version 6 (GraphPad Software Inc, La Jolla, CA, USA).
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